
Sabba Nazhand
65 posts

Sabba Nazhand
@SabbaNazhand
Founder @ Safar | Neuroplastogen Therapy OS | Fractional GTM | Father | Psychedelics | Fitness | My ancestors were mystics-finding ways to reconnect with them.




FDA continues to see unapproved GLP-1s being mass marketed. These drugs can be risky and ineffective. We’ll continue to go after companies that are violating our regulations. We work for the American people.



Introducing Claude Managed Agents: everything you need to build and deploy agents at scale. It pairs an agent harness tuned for performance with production infrastructure, so you can go from prototype to launch in days. Now in public beta on the Claude Platform.


FDA has issued 7 warning letters linked to 20+ violative products with concerns about GLP-1 and other products sold to consumers marked for “research purposes” or “not for human consumption”. These products may pose serious health risks. Do not use or purchase unapproved GLP-1 products marketed for research purposes. fda.gov/inspections-co…


The psychedelic movement is growing. Just had a call with someone on X who reached out to me because of my psychedelic content. He had a profound experience with magic mushrooms, and is now joining the cause. We will change the world, together. ❤️


The New Yorker just lab-tested research peptides from a popular online vendor. BPC-157: contained lead. TB-500: contained endotoxins. CJC-1295: less than 42% of the labeled dose. This is what people are injecting into their bodies. The peptides aren't the problem. The supply chain is. This is exactly why the FDA reclassification matters moving these compounds into regulated compounding pharmacies with cGMP standards and real quality control.


Sam Altman is “unconstrained by truth,” an OpenAI board member told @ronanfarrow.bsky.social and Andrew Marantz. newyorkermag.visitlink.me/DrbIzE















